Single-Cell Landscape of Liver Cancer in Response to Immunotherapy.
作者信息
Diao Feiyu
机构信息
Department of General Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
出版信息
Asia Pac J Oncol Nurs. 2021 Oct 4;8(6):591-593. doi: 10.4103/apjon.apjon-2165. eCollection 2021 Nov-Dec.
Abstract
摘要
相似文献
1
Single-Cell Landscape of Liver Cancer in Response to Immunotherapy.肝癌对免疫治疗反应的单细胞图谱
Asia Pac J Oncol Nurs. 2021 Oct 4;8(6):591-593. doi: 10.4103/apjon.apjon-2165. eCollection 2021 Nov-Dec.
2
Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy.甲状腺癌免疫细胞浸润景观的特征分析以改善免疫治疗
Front Mol Biosci. 2021 Nov 1;8:714053. doi: 10.3389/fmolb.2021.714053. eCollection 2021.
3
The intra-class heterogeneity of immunophenotyping and immune landscape in oesophageal cancer and clinical implications.食管癌免疫表型和免疫图谱的组内异质性及其临床意义。
Ann Med. 2021 Dec;53(1):626-638. doi: 10.1080/07853890.2021.1912385.
4
An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.基于免疫图谱的预后标志物可预测结直肠癌患者的免疫状态和免疫治疗反应。
Life Sci. 2020 Nov 15;261:118368. doi: 10.1016/j.lfs.2020.118368. Epub 2020 Sep 1.
5
Identifying the optimal anticancer targets from the landscape of a cancer-immunity interaction network.从癌症-免疫相互作用网络格局中识别最佳抗癌靶点。
Phys Chem Chem Phys. 2017 Mar 15;19(11):7642-7651. doi: 10.1039/c6cp07767f.
6
Imaging of T-cell Responses in the Context of Cancer Immunotherapy.癌症免疫治疗背景下的 T 细胞反应影像学。
Cancer Immunol Res. 2021 May;9(5):490-502. doi: 10.1158/2326-6066.CIR-20-0678.
7
Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy.甲状腺乳头癌免疫特征分析揭示了不同的肿瘤免疫原性及其对免疫治疗的影响。
Oncoimmunology. 2021 Sep 7;10(1):e1964189. doi: 10.1080/2162402X.2021.1964189. eCollection 2021.
8
The Immunotherapy Landscape in Renal Cell Carcinoma.肾细胞癌的免疫治疗全景。
BioDrugs. 2020 Dec;34(6):733-748. doi: 10.1007/s40259-020-00449-4.
9
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.利用单细胞分析技术了解肝癌肿瘤细胞异质性及其对免疫治疗的影响。
J Hepatol. 2021 Mar;74(3):700-715. doi: 10.1016/j.jhep.2020.11.036. Epub 2020 Nov 30.
10
Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas.全面分析垂体腺瘤的免疫图谱：免疫治疗对垂体腺瘤的影响。
J Neurooncol. 2020 Sep;149(3):473-487. doi: 10.1007/s11060-020-03636-z. Epub 2020 Oct 9.
引用本文的文献
1
Discovery of FOCAD: An Important Gene in Liver Cirrhosis.FOCAD的发现：肝硬化中的一个重要基因。
Glob Med Genet. 2022 Dec 8;9(4):263-264. doi: 10.1055/s-0042-1758351. eCollection 2022 Dec.
本文引用的文献
1
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.单细胞图谱揭示肝癌和肝内胆管癌治疗过程中的肿瘤细胞演变。
J Hepatol. 2021 Dec;75(6):1397-1408. doi: 10.1016/j.jhep.2021.06.028. Epub 2021 Jun 30.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.肝细胞癌的分子分型：迈向精准医学的一步。
Cancer Commun (Lond). 2020 Dec;40(12):681-693. doi: 10.1002/cac2.12115. Epub 2020 Dec 8.
4
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution.肺癌进化过程中出现高可塑性细胞状态。
Cancer Cell. 2020 Aug 10;38(2):229-246.e13. doi: 10.1016/j.ccell.2020.06.012. Epub 2020 Jul 23.
5
Cancer burden of major cancers in China: A need for sustainable actions.中国主要癌症的癌症负担：需要采取可持续行动。
Cancer Commun (Lond). 2020 May;40(5):205-210. doi: 10.1002/cac2.12025. Epub 2020 May 2.
6
Understanding the Cause and Consequence of Tumor Heterogeneity.理解肿瘤异质性的原因和后果。
Trends Cancer. 2020 Apr;6(4):267-271. doi: 10.1016/j.trecan.2020.01.010. Epub 2020 Feb 13.
7
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.肿瘤细胞多样性驱动肝癌微环境重编程。
Cancer Cell. 2019 Oct 14;36(4):418-430.e6. doi: 10.1016/j.ccell.2019.08.007. Epub 2019 Oct 3.
8
Pathological transition as the arising mechanism for drug resistance in lung cancer.病理性转变作为肺癌耐药产生的机制。
Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8.
9
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?中国当前癌症形势：2018 年全球癌症统计数据带来的是好消息还是坏消息？
Cancer Commun (Lond). 2019 Apr 29;39(1):22. doi: 10.1186/s40880-019-0368-6.
10
The biological and clinical challenge of liver cancer heterogeneity.肝癌异质性的生物学和临床挑战。
Hepat Oncol. 2014 Oct;1(4):349-353. doi: 10.2217/hep.14.18. Epub 2014 Dec 11.
Zotero 插件